Soleno Therapeutics (NASDAQ:SLNO) Receives “Neutral” Rating from Cantor Fitzgerald

Soleno Therapeutics (NASDAQ:SLNO)‘s stock had its “neutral” rating reiterated by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $53.00 target price on the stock, down from their previous target price of $123.00. Cantor Fitzgerald’s price target would suggest a potential upside of 1.56% from the stock’s current price.

Several other research analysts have also weighed in on SLNO. Wells Fargo & Company reduced their target price on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen cut Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Zacks Research lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Finally, Oppenheimer lowered their target price on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating for the company in a research note on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Soleno Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $97.10.

Soleno Therapeutics Trading Up 32.1%

SLNO traded up $12.70 during mid-day trading on Monday, hitting $52.19. The stock had a trading volume of 33,562,619 shares, compared to its average volume of 2,146,771. The stock’s fifty day simple moving average is $37.80 and its 200-day simple moving average is $47.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of 226.94 and a beta of -2.81. Soleno Therapeutics has a 1-year low of $29.43 and a 1-year high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. As a group, research analysts forecast that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after acquiring an additional 189 shares in the last quarter. Raymond James Financial Inc. bought a new position in Soleno Therapeutics in the second quarter valued at approximately $25,000. Avanza Fonder AB increased its position in shares of Soleno Therapeutics by 11.2% during the 4th quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after purchasing an additional 323 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Soleno Therapeutics by 11.9% during the 3rd quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after purchasing an additional 340 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Soleno Therapeutics by 2.4% during the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock worth $1,055,000 after purchasing an additional 360 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Key Stories Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for $53.00 per share in cash, valuing the company at roughly $2.9B; the deal highlights VYKAT XR’s strategic and commercial value and is the primary catalyst lifting SLNO shares. Read More.
• Positive Sentiment: Major financial press and wire services confirmed the transaction (additional independent coverage), increasing deal credibility and investor confidence that the cash takeover will proceed through standard regulatory and shareholder approvals. Read More.
• Neutral Sentiment: Trading in SLNO was briefly halted ahead of the announcement for “news pending,” which is consistent with a planned deal release and explains the pre‑market volatility; a conference call from Neurocrine was scheduled to discuss transaction details. (News halt entry reported 06:55 AM.)
• Negative Sentiment: Multiple securities class action lawsuits and investor‑rights firms are actively pursuing claims related to prior disclosures around DCCR/VYKAT XR launch disruptions (class period cited Mar 26–Nov 4, 2025). These suits could lead to recovery actions or attempts to extract higher consideration, potentially complicating closing or increasing transaction costs. Read More.
• Negative Sentiment: A shareholder investigation by Halper Sadeh LLC is probing whether Soleno’s board obtained a fair price for shareholders — such probes often precede litigation seeking a higher bid or other remedies and can create deal uncertainty. Read More.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.